Assembly Actions -
Lowercase Senate Actions - UPPERCASE |
|
---|---|
Feb 01, 2022 |
referred to insurance |
Senate Bill S8193
2021-2022 Legislative Session
Sponsored By
(D, WF) 46th Senate District
Archive: Last Bill Status - In Senate Committee Insurance Committee
- Introduced
-
- In Committee Assembly
- In Committee Senate
-
- On Floor Calendar Assembly
- On Floor Calendar Senate
-
- Passed Assembly
- Passed Senate
- Delivered to Governor
- Signed By Governor
Actions
co-Sponsors
(D) Senate District
2021-S8193 (ACTIVE) - Details
- See Assembly Version of this Bill:
- A9250
- Current Committee:
- Senate Insurance
- Law Section:
- Insurance Law
- Laws Affected:
- Amd §4902, Ins L; amd §4902, Pub Health L
- Versions Introduced in 2023-2024 Legislative Session:
-
S2682, A582
2021-S8193 (ACTIVE) - Sponsor Memo
BILL NUMBER: S8193 SPONSOR: BRESLIN TITLE OF BILL: An act to amend the insurance law and the public health law, in relation to protecting certain therapeutic classes from step therapy PURPOSE OR GENERAL IDEA OF BILL: The purpose of this bill is to prevent plans from implementing step therapy policies for certain progressive diseases. SUMMARY OF PROVISIONS: Section one amends section 4902 of the insurance law to prohibit a utilization review agent from applying a step therapy protocol to medically necessary prescription drugs in dermatologic, hematology, ophthalmologic, rheumatic, gastrointestinal, neurology, and oncology therapeutic classes, including non-formulary drugs. Section two amends section 4902 of the public health law to reflect the
2021-S8193 (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 8193 I N S E N A T E February 1, 2022 ___________ Introduced by Sen. BRESLIN -- read twice and ordered printed, and when printed to be committed to the Committee on Insurance AN ACT to amend the insurance law and the public health law, in relation to protecting certain therapeutic classes from step therapy THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. Subsection (a) of section 4902 of the insurance law is amended by adding a new paragraph 14 to read as follows: (14) WHEN ESTABLISHING A STEP THERAPY PROTOCOL, A UTILIZATION REVIEW AGENT SHALL ENSURE THAT SUCH PROTOCOL SHALL NOT APPLY TO MEDICALLY NECESSARY PRESCRIPTION DRUGS IN THE DERMATOLOGIC, HEMATOLOGY, OPHTHALMO- LOGIC, RHEUMATIC, GASTROINTESTINAL, NEUROLOGY, AND ONCOLOGY THERAPEUTIC CLASSES, INCLUDING NON-FORMULARY DRUGS. § 2. Section 4902 of the public health law is amended by adding a new subdivision 5 to read as follows: 5. WHEN ESTABLISHING A STEP THERAPY PROTOCOL, A UTILIZATION REVIEW AGENT SHALL ENSURE THAT SUCH PROTOCOL SHALL NOT APPLY TO MEDICALLY NECESSARY PRESCRIPTION DRUGS IN THE DERMATOLOGIC, HEMATOLOGY, OPHTHALMO- LOGIC, RHEUMATIC, GASTROINTESTINAL, NEUROLOGY, AND ONCOLOGY THERAPEUTIC CLASSES, INCLUDING NON-FORMULARY DRUGS. § 3. This act shall take effect immediately. EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted. LBD14452-01-2
Comments
Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.
Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.
Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.